Dados B3 › JBSS3 × BRFS3
JBSS3 × BRFS3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | JBSS3 | BRFS3 | year |
|---|---|---|---|
| ROE | 24.8% | 23.2% | 2025 |
| ROIC | 14.4% | 19.5% | 2025 |
| ROA | 5.0% | 5.0% | 2025 |
| Gross margin | 13.1% | 25.2% | 2025 |
| EBIT margin | 4.9% | 10.2% | 2025 |
| Net margin | 2.6% | 5.1% | 2025 |
| Net debt/EBITDA | 2.49x | 1.42x | 2025 |
| Current ratio | 1.60x | 1.36x | 2025 |
| Revenue growth (1y) | 15.3% | 6.0% | 2025 |
| Revenue growth (5y CAGR) | 12.2% | 10.5% | 2025 |
| Piotroski F-Score | 7/9 | 4/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | JBSS3 | BRFS3 | year |
|---|---|---|---|
| P/E | 9.40x | 9.59x | 2024 |
| P/B | 2.02x | 2.04x | 2024 |
| EV/EBITDA | 4.90x | 3.81x | 2024 |
| FCF yield | 17.1% | 31.8% | 2024 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 14:51 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.